Picture of Actinogen Medical logo

ACW — Actinogen Medical Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-25.28%
3m-21.52%
6m-45.79%
1yr-17.71%
Volume Change (%)
10d/3m-28.33%
Price vs... (%)
52w High-64.05%
50d MA-17.79%
200d MA-36.79%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value5.13
Price to Tang. Book5.81
Price to Free Cashflown/a
Price to Sales4,912.83
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-29.69%
Return on Equity-36.73%
Operating Margin-28590.45%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202230th Jun 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Actinogen Medical EPS forecast chart

Profile Summary

Actinogen Medical Limited is an Australia-based biotechnology company. The Company is focused on developing therapy for neurological diseases associated with dysregulated brain cortisol. Its lead compound, Xanamem, is a therapy for Alzheimer's disease, fragile x syndrome, major depressive disorder and other neurological diseases. It is designed to block the production of cortisol the stress hormone in the brain. Xanamem is an inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the central nervous system. It is an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in neuropsychiatric diseases. The Company focuses on developing Phase II clinical trial evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer.

Directors

Last Annual
June 30th, 2021
Last Interim
December 31st, 2021
Incorporated
March 26th, 1999
Public Since
October 12th, 2007
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
1,774,846,595

ACW Share Price Performance

Upcoming Events for ACW

Full Year 2022 Actinogen Medical Ltd Earnings Release

Actinogen Medical Ltd Annual Shareholders Meeting

Similar to ACW

Picture of Adalta logo

Adalta

au flag iconAustralian Stock Exchange - SEATS

Picture of Alterity Therapeutics logo

Alterity Therapeutics

au flag iconAustralian Stock Exchange - SEATS

Picture of Amplia Therapeutics logo

Amplia Therapeutics

au flag iconAustralian Stock Exchange - SEATS

Picture of Anatara Lifesciences logo

Anatara Lifesciences

au flag iconAustralian Stock Exchange - SEATS

Picture of Anteotech logo

Anteotech

au flag iconAustralian Stock Exchange - SEATS

FAQ

Or unlock with your email

Or unlock with your email